Table 1

Baseline Characteristics of the Study Population

Zotarolimus-Eluting Stent (n = 1,502)Biolimus-Eluting Stent (n = 1,497)p Value
Age (yrs)65.7 ± 10.765.8 ± 10.90.66
Men1,144 (76.2)1,135 (75.8)0.82
Diabetes mellitus265/1,502 (17.6)270/1,497 (18.0)0.78
Arterial hypertension872/1,460 (59.7)850/1,462 (58.1)0.38
Hypercholesterolemia871/1,470 (59.3)867/1,466 (59.1)0.95
Current smoker443/1,441 (30.7)439/1,431 (30.7)0.97
Body mass index (kg/m2)26.9 ± 5.426.9 ± 5.50.97
Previous myocardial infarction275/1,468 (18.7)288/1,464 (19.7)0.52
Previous percutaneous coronary intervention277/1,478 (18.7)324/1,475 (22.0)0.03
Previous coronary artery bypass grafting126/1,499 (8.4)101/1,494 (6.8)0.09
Indication for percutaneous coronary intervention0.11
 Stable angina685 (45.6)670 (44.8)
 Non–ST-segment elevation MI/unstable angina465 (31.0)508 (33.9)
 ST-segment elevation MI295 (19.6)253 (16.9)
 Other57 (3.8)66 (4.4)
Number of lesions0.10
 11,131 (75.3)1,175 (78.5)
 2298 (19.8)270 (18.0)
 361 (4.1)41 (2.7)
 >312 (0.8)11 (0.7)
Number of lesions per patient1.3 (0.6)1.3 (0.5)0.03
Index lesion0.66
 Stent thrombosis18 (1.0)12 (0.7)
 In-stent restenosis43 (2.3)45 (2.5)
 Non-in-stent restenosis13 (0.7)16 (0.9)
Target vessel location (%)0.73
 Left main17 (0.9)21 (1.2)
 Left anterior descending758 (40.3)743 (41.5)
 Left circumflex447 (23.8)430 (24.0)
 Right coronary637 (33.9)579 (32.3)
 Saphenous vein graft23 (1.2)18 (1.0)
Lesion type0.28
 A285 (15.2)289 (16.1)
 B1544 (28.9)558 (31.2)
 B2396 (21.1)354 (19.8)
 C656 (34.9)590 (32.9)
Chronic total occlusion lesions82 (4.4)85 (4.9)0.55
Bifurcation lesions226 (12.2)229 (13.1)0.44
Lesion length >18 mm558 (29.7)491 (27.4)0.13
Lesion length (mm)16.0 (12.0–25.0)15.0 (10.0–25.0)0.02
Reference vessel size (mm)3.2 (2.9–3.5)3.0 (2.8–3.5)0.11

Values are mean ± SD, n (%), n/N (%), or median (interquartile range). Some of the 2,999 participants’ data is missing for some variables (cases/sample size number) because it was not recorded in the Western Denmark Heart Registry.

MI = myocardial infarction.